Tweet
Vaccines designed to protect people from the influenza virus tend to concentrate on hemagglutinin, one of the two prominently displayed proteins on the surface of the virus and the primary target for influenza prevention.
In the April 5, 2018, issue of the journal Cell, however, teams led by Patrick Wilson at the University of Chicago Medicine and Florian Krammer at the Icahn School of Medicine at Mt. Sinai Hospital in New York City argue that placing greater emphasis on the comparatively neglected protein, neuraminidase, could substantially decrease infection rates and reduce disease severity for those infected with the virus.
These two viral-surface glycoproteins have distinct roles. Hemagglutinin enables the virus to attach to a host's cell membranes and enter that person's cells. Once inside the cell, the virus makes multiple copies of itself. These copies then prepare to burst out of their hijacked cell and infect more cells.
...
In the April 5, 2018, issue of the journal Cell, however, teams led by Patrick Wilson at the University of Chicago Medicine and Florian Krammer at the Icahn School of Medicine at Mt. Sinai Hospital in New York City argue that placing greater emphasis on the comparatively neglected protein, neuraminidase, could substantially decrease infection rates and reduce disease severity for those infected with the virus.
These two viral-surface glycoproteins have distinct roles. Hemagglutinin enables the virus to attach to a host's cell membranes and enter that person's cells. Once inside the cell, the virus makes multiple copies of itself. These copies then prepare to burst out of their hijacked cell and infect more cells.
...
Comment